Latest news
Altimmune announces RECLAIM trial met primary endpoint - TipRanksTipRanks · Wed, 29 Jul 2026 07:17:18 GMTAltimmune's GLP-1 drug could help reduce heavy drinking linked to alcohol use disorder - FirstWord PharmaFirstWord Pharma · Tue, 28 Jul 2026 22:25:16 GMTALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - TradingViewTradingView · Tue, 28 Jul 2026 18:42:00 GMTAltimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Asianet NewsableAsianet Newsable · Tue, 28 Jul 2026 13:50:01 GMTALT: Pemvidutide significantly reduced heavy drinking and improved key outcomes in AUD Phase 2 trial - TradingViewTradingView · Tue, 28 Jul 2026 11:25:27 GMTAltimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD - TradingViewTradingView · Tue, 28 Jul 2026 11:13:01 GMTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Yahoo! Finance CanadaYahoo! Finance Canada · Tue, 28 Jul 2026 11:00:00 GMTAltimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMT